News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Sucampo Pharmaceuticals, Inc. (SCMP) Announces New Data On AMITIZA And Opioid-Induced Constipation Published Online In Pain Medicine Journal


5/6/2014 9:54:09 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

BETHESDA, Md., May 6, 2014 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, announced that its recent study, "A Randomized Study of Lubiprostone for Opioid-Induced Constipation in Patients with Chronic Noncancer Pain," has been published online in the medical journal, Pain Medicine. The study examines the efficacy and safety of AMITIZA ® (oral lubiprostone) for relieving symptoms of opioid-induced constipation (OIC) in chronic non-cancer pain.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES